A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.
調査の概要
詳細な説明
In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).
In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Crystal Wang
- 電話番号:+86-021-60332455
- メール:wangjingru@cstonepharma.com
研究場所
-
-
New South Wales
-
North Ryde、New South Wales、オーストラリア、2109
- Macquarie University
-
主任研究者:
- John Park, Dr
-
Randwick、New South Wales、オーストラリア、2031
- Scientia Clinical Research Ltd
-
主任研究者:
- Charlotte lemech, Dr
-
-
Victoria
-
Clayton、Victoria、オーストラリア、3168
- Monash Medical Centre
-
主任研究者:
- Sophia Frentzas, Dr
-
-
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200123
- Shanghai East Hospital
-
主任研究者:
- Caicun Zhou
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Being ≥ 18 years of age on the day of signing informed consent.
- Pathologically or cytologically confirmed, unresectable advanced solid tumors.
- Participants must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Life expectancy ≥ 3 months.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration
Exclusion Criteria:
- Has disease that is suitable for local treatment administered with curative intent.
- Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
- Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
- Has uncontrolled pleural effusion, pericardial effusion, or ascites.
- Has immune deficient disease or received systemic immunosuppressive treatment.
- Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
- Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
- Has active infections requiring systemic therapy.
- Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
- Insufficient washout from prior anti-tumor therapy.
- Received live vaccine within 28 days prior to first dose.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- History of hypersensitivity to excipients of study drug or any monoclonal antibody.
- Any toxic effects of prior therapy unresolved to Grade ≤1.
- Pregnant or breastfeeding women.
- Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose Escalation
Participants will be administered escalating doses of CS5006. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
|
実験的:Dose Expansion
Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
[用量拡大] RECIST v1.1 に従って研究者によって評価された客観的奏効率 (ORR)
時間枠:最長約2年
|
最長約2年
|
|
|
[Dose Escalation] The incidence and severity of adverse events (AEs)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
時間枠:Cycle 1 (Up to 21 Days)
|
Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT). |
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
時間枠:Up to approximately 2 years
|
The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range. |
Up to approximately 2 years
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
[用量漸増] RECIST v1.1 に従って研究者によって評価された客観的奏効率 (ORR)
時間枠:最長約2年
|
最長約2年
|
|
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Expansion] The incidence and severity of adverse events (AEs)
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Clearance (CL) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
時間枠:Up to approximately 2 years
|
Up to approximately 2 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CS5006-101
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。